CSL is in a strong position as the leading supplier of plasma-derived products globally, including treatments for haemophilia, inherited immune disorders (IID) and other rare diseases. It has generated consistent growth through strategic acquisitions to build scale combined with organic growth from novel therapeutics and value-added products such as sub-cutaneously injected formulations of IV therapies. ROE was 47% in FY16 and annual shareholder returns have averaged 27.6% since listing in 1994.

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central